A Phase 1B Study of AZD9291 in Combination With Navitoclax in EGFR-Mutant Non-Small Cell Lung Cancer Following Resistance to Initial EGFR Kinase Inhibitor
Phase of Trial: Phase I
Latest Information Update: 13 Mar 2018
At a glance
- Drugs Navitoclax (Primary) ; Osimertinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 26 Jan 2018 Planned primary completion date changed from 30 Dec 2017 to 30 Jul 2019.
- 10 Jun 2017 Biomarkers information updated
- 07 Apr 2016 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.